The higher efficacy of PI3K-AKT-mTOR and PARP inhibitors beyond BRCA deficiency, using a double PI3K-mTOR inhibitor (GDC-0980) and olaparib have also been demonstrated in breast cancer [61]. This evidence concerns the gene PARP1 and hyperinsulinemic hypoglycemia, familial, 4.